|Abbott-DNDi Partnership to Boost Innovation for NTDs|
Abbott-DNDi Partnership to Boost Innovation for NTDs
Year Established: 2009
Since 2009, Abbott has provided compounds for DNDi to screen for activity against neglected diseases. Expanding on this relationship, Abbott is now providing DNDi access to research and development expertise of Abbott scientists, selected classes of molecules and accompanying data generated by Abbott that are crucial for the development of effective and accessible new treatments for neglected diseases.
Both DNDi and Abbott share their unique scientific expertise and resources to advance the development of drugs adapted to patient needs.
DNDi gains access to Abbott compounds, data and information to accelerate drug development.
Non-exclusive licensing structure for relevant IP in the neglected diseases field provides flexibility, thus expanding the potential of drug development.
Any resulting products will be provided in endemic countries at the lowest sustainable price to expand patient access.
Typology of Knowledge Network:
Knowledge Type / Focus:
Objective / Knowledge Governance:
Cooperative Research/Product Development
Sharing compounds and scientific and regulatory expertise with the Drugs for Neglected Diseases initiative (DNDi) to advance research on new treatments for NTDs.
Partnering with DNDi to advance a preclinical development program evaluating the use of flubendazole for the treatment of lymphatic filiariasis (elephantiasis) and river blindness.